☆ 4.5 Article

Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker

EUROPEAN UROLOGY FOCUS (2022)

Related references

Note: Only part of the references are listed.

Review Urology & Nephrology

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

Marko Babjuk et al.

Summary: The updated EAU guidelines provide new information on the diagnosis and treatment of NMIBC for clinical practice. Individual risk assessment is crucial in determining the appropriate treatment for patients with different risk levels. Surgical intervention, including radical cystectomy, may be necessary for cases unresponsive to BCG treatment or with high risk of progression.

EUROPEAN UROLOGY (2022)

Add to Collection

Article Urology & Nephrology

Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study

Paulo Gontero et al.

Summary: Comparing the performance of the ADXBLADDER test with cytology in detecting non-muscle-invasive bladder cancer recurrences, ADXBLADDER demonstrated superior sensitivity, specificity, and negative predictive value. The results suggest that ADXBLADDER has the potential to be a more reliable alternative to urine cytology in the follow-up of non-muscle-invasive bladder cancer.

BJU INTERNATIONAL (2021)

Add to Collection

Article Oncology

A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer

Ryan M. Reyes et al.

Summary: The study found challenges in randomizing patients to different surveillance frequencies for non-muscle invasive bladder cancer. Patient willingness to participate was high, but 35.7% declined enrollment due to preference for high frequency surveillance. There were no significant differences in disease recurrence, comfort, and quality of life between patients in the high frequency and low frequency groups, but the high frequency group had higher annual out-of-pocket costs and healthcare system costs.

BLADDER CANCER (2021)

Add to Collection

Review Oncology

Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review

Jur Robert Erica Wolfs et al.

Summary: Established urinary biomarkers have limited effectiveness in the diagnosis and follow-up of NMIBC. Novel urinary biomarkers ADXBLADDER and Bladder EpiCheck show higher sensitivity and negative predictive values, but lower specificity in comparison.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

Add to Collection

Article Urology & Nephrology

Follow-up in non-muscle invasive bladder cancer: facts and future

J. Alfred Witjes

Summary: Patients with non-muscle invasive bladder cancer (NMIBC) face challenges in frequent and suboptimal follow-up, with low levels of evidence and limitations in current tools. Urinary markers may offer a promising solution, potentially reducing patient burden and healthcare costs in the future.

WORLD JOURNAL OF UROLOGY (2021)

Add to Collection

Editorial Material Endocrinology & Metabolism

Introduction to diagnostic test accuracy studies

Alice J. Sitch et al.

Summary: Diagnostic accuracy studies are crucial for evaluating diagnostic tests. Researchers should choose appropriate study designs, analyze results using correct methods, and avoid exaggerating conclusions, while also considering the clinical context for balancing sensitivity and specificity. Transparent reporting using the STARD checklist is recommended for test accuracy studies.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)

Add to Collection

Article Urology & Nephrology

Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert(R) Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer

Barrett Cowan et al.

Summary: The study evaluated the performance of Xpert Bladder Cancer Monitor as a predictor of tumor recurrence in NMIBC patients, showing high sensitivity and negative predictive value for high-grade cancer. Patients with positive Xpert but negative cystoscopy results have a higher risk of recurrence and require close surveillance.

BJU INTERNATIONAL (2021)

Add to Collection

Article Oncology

Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer

Emanuela Trenti et al.

CANCER CYTOPATHOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC)

Michael E. Rezaee et al.

PLOS ONE (2020)

Add to Collection

Article Oncology

Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial

Natalya Benderska-Soeder et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)

Add to Collection

Article Urology & Nephrology

Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study

Morgan Roupret et al.

JOURNAL OF UROLOGY (2020)

Add to Collection

Article Oncology

The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer

Florian R. Schroeck et al.

CANCER (2019)

Add to Collection

Article Urology & Nephrology

Overuse of Cystoscopic Surveillance Among Patients With Low-risk Non-Muscle-invasive Bladder Cancer - A National Study of Patient, Provider, and Facility Factors

David S. Han et al.

UROLOGY (2019)

Add to Collection

Article Urology & Nephrology

Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer

David D'Andrea et al.

BJU INTERNATIONAL (2019)

Add to Collection

Article Urology & Nephrology

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer

F. Johannes P. van Valenberg et al.

EUROPEAN UROLOGY (2019)

Add to Collection

Article Pathology

Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer

Carolina D'Elia et al.

JOURNAL OF CLINICAL PATHOLOGY (2019)

Add to Collection

Article Urology & Nephrology

Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories

Matthew Mossanen et al.

WORLD JOURNAL OF UROLOGY (2019)

Add to Collection

Article Urology & Nephrology

Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives

Rashid K. Sayyid et al.

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2018)

Add to Collection

Article Urology & Nephrology

Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project

Rodolfo Hurle et al.

JOURNAL OF UROLOGY (2018)

Add to Collection

Review Urology & Nephrology

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer

Francesco Soria et al.

WORLD JOURNAL OF UROLOGY (2018)

Add to Collection

Article Oncology

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial

J. Alfred Witjes et al.

EUROPEAN UROLOGY ONCOLOGY (2018)

Add to Collection

Review Health Care Sciences & Services

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

G. Mowatt et al.

HEALTH TECHNOLOGY ASSESSMENT (2010)

Add to Collection

Article Oncology

Receiver Operating Characteristic Curve in Diagnostic Test Assessment

Jayawant N. Mandrekar

JOURNAL OF THORACIC ONCOLOGY (2010)

Add to Collection

Article Urology & Nephrology

Safety of Active Surveillance Program for Recurrent Nonmuscle-invasive Bladder Carcinoma

V. Hernandez et al.

UROLOGY (2009)

Add to Collection

Article Health Care Sciences & Services

Decision curve analysis: A novel method for evaluating prediction models

Andrew J. Vickers et al.

MEDICAL DECISION MAKING (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.